AR069135A1 - Compuesto de alfa-(n-sulfonamido) acetamida como un inhibidor de produccion de peptido beta amiloide - Google Patents
Compuesto de alfa-(n-sulfonamido) acetamida como un inhibidor de produccion de peptido beta amiloideInfo
- Publication number
- AR069135A1 AR069135A1 ARP080104770A ARP080104770A AR069135A1 AR 069135 A1 AR069135 A1 AR 069135A1 AR P080104770 A ARP080104770 A AR P080104770A AR P080104770 A ARP080104770 A AR P080104770A AR 069135 A1 AR069135 A1 AR 069135A1
- Authority
- AR
- Argentina
- Prior art keywords
- sulfonamide
- acetamide
- alpha
- composite
- amyloid peptide
- Prior art date
Links
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 title 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Su composicion farmacéutica, procedimientos de la misma y un procedimiento para el tratamiento de la enfermedad de Alzheimer y otras afecciones asociadas con péptido b-amiloide. Reivindicacion 1: El compuesto caracterizado porque es (2R)-2-[[(4-clorofenil)sulfonil][[2-fluoro-4-(1,2,4oxadiazol-3-iI)feniI]metil]amino]-5,5,5-trifIuoropentanamida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98411807P | 2007-10-31 | 2007-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069135A1 true AR069135A1 (es) | 2009-12-30 |
Family
ID=40193955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104770A AR069135A1 (es) | 2007-10-31 | 2008-10-30 | Compuesto de alfa-(n-sulfonamido) acetamida como un inhibidor de produccion de peptido beta amiloide |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8084477B2 (es) |
| EP (3) | EP2471769A1 (es) |
| JP (1) | JP5460605B2 (es) |
| KR (1) | KR20100075575A (es) |
| CN (2) | CN102718689A (es) |
| AR (1) | AR069135A1 (es) |
| AT (1) | ATE502022T1 (es) |
| AU (1) | AU2008319122A1 (es) |
| BR (1) | BRPI0818837A2 (es) |
| CA (1) | CA2704360A1 (es) |
| CL (1) | CL2008003271A1 (es) |
| CO (1) | CO6270332A2 (es) |
| CY (2) | CY1112337T1 (es) |
| DE (1) | DE602008005636D1 (es) |
| DK (2) | DK2205575T3 (es) |
| EA (2) | EA016447B1 (es) |
| ES (2) | ES2361283T3 (es) |
| HR (2) | HRP20110219T1 (es) |
| IL (1) | IL205406A0 (es) |
| MX (1) | MX2010004319A (es) |
| NZ (1) | NZ584545A (es) |
| PE (1) | PE20091394A1 (es) |
| PL (2) | PL2295417T3 (es) |
| PT (2) | PT2295417E (es) |
| SG (2) | SG174044A1 (es) |
| SI (2) | SI2295417T1 (es) |
| TW (1) | TW200927099A (es) |
| WO (1) | WO2009058552A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1465861T3 (da) | 2001-12-20 | 2009-08-31 | Bristol Myers Squibb Co | Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere |
| US8093276B2 (en) * | 2007-10-31 | 2012-01-10 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| CA2755738A1 (en) * | 2009-03-19 | 2010-09-23 | Bristol-Myers Squibb Company | A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| US8044077B2 (en) * | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
| US7977362B2 (en) | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
| US8252821B2 (en) * | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| TW201043269A (en) * | 2009-04-14 | 2010-12-16 | Bristol Myers Squibb Co | Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| US8841458B2 (en) * | 2010-03-12 | 2014-09-23 | Nippon Soda Co., Ltd. | Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative |
| WO2012040444A2 (en) * | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Treatment of patients with incipient alzheimer's disease |
| JP2013542973A (ja) * | 2010-11-22 | 2013-11-28 | ノスシラ、ソシエダッド、アノニマ | 神経変性疾患または神経変性状態を治療するためのビピリジンスルホンアミド誘導体 |
| WO2014047370A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl dibenzodiazepinone compounds |
| EP2897960B1 (en) | 2012-09-21 | 2016-08-03 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds as notch inhibitors |
| JP2015529252A (ja) | 2012-09-21 | 2015-10-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | フルオロアルキル−１，４−ベンゾジアゼピノン化合物 |
| EP2897944B1 (en) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinone compounds |
| CN103058913B (zh) * | 2012-12-13 | 2015-09-30 | 江苏弘和药物研发有限公司 | 5-氯异吲哚酮的合成方法 |
| CN104163784B (zh) * | 2014-06-20 | 2019-01-08 | 湖南天地恒一制药有限公司 | 一种奥拉西坦的合成工艺 |
| KR20190098998A (ko) | 2016-12-16 | 2019-08-23 | 파이프라인 테라퓨틱스, 아이엔씨. | 달팽이관 시냅스질환의 치료 방법 |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| CN107935957B (zh) * | 2017-12-02 | 2020-08-21 | 江苏仁明生物科技有限公司 | 一种合成高纯度沙坦侧链ttbb的方法 |
| IL317554A (en) | 2018-06-01 | 2025-02-01 | Novartis Ag | Anti-BCMA binding molecules and their uses |
| CN108640886A (zh) * | 2018-08-01 | 2018-10-12 | 余锋 | 一种作为β-淀粉样肽产生的抑制剂BMS-708163的合成方法 |
| TW202115114A (zh) | 2019-06-24 | 2021-04-16 | 瑞士商諾華公司 | 針對靶向ｂ細胞成熟抗原的多特異抗體之給藥方案及組合療法 |
| CN113466367B (zh) * | 2021-06-25 | 2023-04-14 | 深圳万乐药业有限公司 | 乌苯美司原料药中α-苯乙胺杂质检测方法 |
| CN113816874B (zh) * | 2021-10-30 | 2024-01-26 | 大连双硼医药化工有限公司 | 一种合成4-氰基-2-氟苄醇的工艺方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5274094A (en) * | 1990-08-15 | 1993-12-28 | British Bio-Technology Limited | Production of heterobicyclic containing benzene sulfonamides |
| GB9202791D0 (en) * | 1992-02-11 | 1992-03-25 | British Bio Technology | Compounds |
| US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| PT874836E (pt) * | 1995-11-17 | 2003-02-28 | Warner Lambert Co | Inibidores com sulfonamida de metaloproteinases de matriz |
| WO1998003166A1 (en) | 1996-07-22 | 1998-01-29 | Monsanto Company | Thiol sulfonamide metalloprotease inhibitors |
| JPH11343279A (ja) | 1998-03-16 | 1999-12-14 | Shionogi & Co Ltd | スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤 |
| AU766192B2 (en) | 1999-01-27 | 2003-10-09 | Wyeth Holdings Corporation | Acetylenic sulfonamide thiol tace inhibitors |
| US6313123B1 (en) * | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
| PL349781A1 (en) | 1999-02-26 | 2002-09-09 | Merck & Co Inc | Novel sulfonamide compounds and uses thereof |
| US6541467B1 (en) * | 2000-04-14 | 2003-04-01 | Corvas International, Inc. | Thrombin inhibitors having a lactam at P3 |
| US20020115640A1 (en) * | 2000-11-30 | 2002-08-22 | Claiborne Akiyo K. | Farnesyltransferase inhibitors |
| IL159140A0 (en) * | 2001-12-14 | 2004-06-01 | Raytheon Co | Precisely aligned lens structure and a method for its fabrication |
| DK1465861T3 (da) * | 2001-12-20 | 2009-08-31 | Bristol Myers Squibb Co | Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere |
| CN1653064A (zh) * | 2002-02-28 | 2005-08-10 | 阿斯特拉曾尼卡有限公司 | 噁唑烷酮衍生物、其制备方法以及包含它们的药用组合物 |
| ATE362368T1 (de) * | 2003-03-20 | 2007-06-15 | Santhera Pharmaceuticals Ch | Substituierte piperidin- und piperazin-derivative als melanocortin-4 receptor modulatoren |
| NZ542468A (en) * | 2003-03-31 | 2009-01-31 | Wyeth Corp | Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof |
| US7144894B2 (en) * | 2004-09-23 | 2006-12-05 | Bristol-Myers Squibb Company | Sulfonamide bicyclic compounds |
| CA2637615A1 (en) * | 2006-02-17 | 2007-08-30 | Wyeth | Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols |
| PE20080169A1 (es) * | 2006-02-17 | 2008-04-11 | Wyeth Corp | Metodo para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios |
| US8633179B2 (en) | 2007-03-13 | 2014-01-21 | The Trustees Of Columbia University In The City Of New York | Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids |
| WO2009005688A2 (en) | 2007-06-29 | 2009-01-08 | Trustees Of Columbia University In The City Of New York | Activating mutations in notch-1 |
| US8093276B2 (en) | 2007-10-31 | 2012-01-10 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| US8044077B2 (en) * | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
-
2008
- 2008-10-10 US US12/249,180 patent/US8084477B2/en active Active
- 2008-10-14 PT PT10190591T patent/PT2295417E/pt unknown
- 2008-10-14 SG SG2011056454A patent/SG174044A1/en unknown
- 2008-10-14 ES ES08843687T patent/ES2361283T3/es active Active
- 2008-10-14 DK DK08843687.8T patent/DK2205575T3/da active
- 2008-10-14 PL PL10190591T patent/PL2295417T3/pl unknown
- 2008-10-14 BR BRPI0818837 patent/BRPI0818837A2/pt not_active IP Right Cessation
- 2008-10-14 SI SI200830775T patent/SI2295417T1/sl unknown
- 2008-10-14 EP EP12159802A patent/EP2471769A1/en not_active Withdrawn
- 2008-10-14 NZ NZ584545A patent/NZ584545A/en not_active IP Right Cessation
- 2008-10-14 DK DK10190591.7T patent/DK2295417T3/da active
- 2008-10-14 AT AT08843687T patent/ATE502022T1/de active
- 2008-10-14 ES ES10190591T patent/ES2390042T3/es active Active
- 2008-10-14 PT PT08843687T patent/PT2205575E/pt unknown
- 2008-10-14 CA CA2704360A patent/CA2704360A1/en not_active Abandoned
- 2008-10-14 AU AU2008319122A patent/AU2008319122A1/en not_active Abandoned
- 2008-10-14 CN CN201210178082XA patent/CN102718689A/zh active Pending
- 2008-10-14 SI SI200830183T patent/SI2205575T1/sl unknown
- 2008-10-14 EP EP10190591A patent/EP2295417B1/en not_active Not-in-force
- 2008-10-14 DE DE602008005636T patent/DE602008005636D1/de active Active
- 2008-10-14 EP EP08843687A patent/EP2205575B1/en not_active Not-in-force
- 2008-10-14 PL PL08843687T patent/PL2205575T3/pl unknown
- 2008-10-14 EA EA201000714A patent/EA016447B1/ru not_active IP Right Cessation
- 2008-10-14 HR HR20110219T patent/HRP20110219T1/hr unknown
- 2008-10-14 SG SG2011056447A patent/SG174043A1/en unknown
- 2008-10-14 KR KR1020107009453A patent/KR20100075575A/ko not_active Withdrawn
- 2008-10-14 EA EA201171439A patent/EA201171439A1/ru unknown
- 2008-10-14 CN CN2008801240109A patent/CN101910141B/zh not_active Expired - Fee Related
- 2008-10-14 WO PCT/US2008/079798 patent/WO2009058552A1/en not_active Ceased
- 2008-10-14 JP JP2010532118A patent/JP5460605B2/ja not_active Expired - Fee Related
- 2008-10-14 MX MX2010004319A patent/MX2010004319A/es active IP Right Grant
- 2008-10-30 CL CL2008003271A patent/CL2008003271A1/es unknown
- 2008-10-30 AR ARP080104770A patent/AR069135A1/es unknown
- 2008-10-31 TW TW097142279A patent/TW200927099A/zh unknown
- 2008-10-31 PE PE2008001866A patent/PE20091394A1/es not_active Application Discontinuation
-
2010
- 2010-04-27 CO CO10049723A patent/CO6270332A2/es not_active Application Discontinuation
- 2010-04-28 IL IL205406A patent/IL205406A0/en unknown
-
2011
- 2011-06-15 CY CY20111100570T patent/CY1112337T1/el unknown
- 2011-11-18 US US13/299,703 patent/US8350084B2/en active Active
-
2012
- 2012-09-04 HR HRP20120703AT patent/HRP20120703T1/hr unknown
- 2012-09-28 CY CY20121100889T patent/CY1113346T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069135A1 (es) | Compuesto de alfa-(n-sulfonamido) acetamida como un inhibidor de produccion de peptido beta amiloide | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| CL2007003583A1 (es) | Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer. | |
| CL2008001215A1 (es) | Compuestos derivados de heterociclos nitrogenados condensados; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, dislipidemia, obesidad y alzheimer. | |
| CL2007002974A1 (es) | Compuestos derivados de benzoimidazol; composicion farmaceutica; y uso para el tratamiento de trastornos asociados con dgat1. | |
| CL2012001685A1 (es) | Análogo peptídico de oxintomodulina, en donde el aminoácido c-terminal es opcionalmente amidado; composición farmacéutica que lo comprende; y su uso en la preparación de un medicamento para el tratamiento de diabetes no insulinodependiente u obesidad. | |
| BR112012011332A2 (pt) | agentes direcionados para gadd45beta | |
| CR8642A (es) | Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos | |
| CL2008000791A1 (es) | Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm | |
| CL2007002920A1 (es) | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. | |
| CL2007000789A1 (es) | Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer. | |
| CL2007002641A1 (es) | Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias. | |
| IL219915A0 (en) | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | |
| CL2008001960A1 (es) | Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide. | |
| CL2007003832A1 (es) | Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades. | |
| CL2007002121A1 (es) | Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab | |
| CL2007002689A1 (es) | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. | |
| CL2007003191A1 (es) | Compuestos derivados de pirimido-piridona, inhibidores de las proteina quinasas; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como artritis, sindrome de colon irritable, sindrome disneico agudo del adulto, epoc y para el | |
| CL2008002411A1 (es) | Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras. | |
| CL2008000910A1 (es) | Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide. | |
| CL2008002162A1 (es) | Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras. | |
| CL2007001630A1 (es) | Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
| CL2007003672A1 (es) | Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad. | |
| CL2007003038A1 (es) | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. | |
| CL2007002619A1 (es) | Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |